



MEN

FIRST CANCER SITE
THYROID

THYROID
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

TIROIDE
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	6644		7072		7072		6644		5604		2757		1023		6644	7072
Person-years ▶	34797		35939		1142		5066		16204		8765		4762		34797	35939
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND THYROID	417	1.22	450	1.27	33	3.01	48	1.03	184	1.19	130	1.46	55	1.05	2.12	2.67
HEAD AND NECK	11	0.65	12	0.68	1	1.80	3	1.26	4	0.52	2	0.46	2	0.79	-0.17	-0.15
ORAL CAVITY	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.12	-0.12
PHARYNX	1	0.24	1	0.24	0	0.00	0	0.00	1	0.54	0	0.00	0	0.00	-0.09	-0.09
LARYNX	10	1.15	11	1.22	1	3.44	3	2.42	3	0.75	2	0.91	2	1.58	0.04	0.06
OESOPHAGUS	3	0.79	4	1.03	1	8.09	0	0.00	3	1.75	0	0.00	0	0.00	-0.02	0.00
STOMACH	25	1.40	25	1.36	0	0.00	3	1.19	10	1.23	10	2.19	2	0.78	0.21	0.18
COLON RECTUM	55	1.19	55	1.15	0	0.00	8	1.30	22	1.06	19	1.56	6	0.84	0.25	0.20
COLON	41	1.31	41	1.27	0	0.00	6	1.45	15	1.07	14	1.69	6	1.22	0.28	0.24
RECTUM	14	0.94	14	0.91	0	0.00	2	0.98	7	1.03	5	1.29	0	0.00	-0.03	-0.04
LIVER	12	0.86	13	0.90	1	2.22	0	0.00	6	0.95	4	1.11	2	0.95	-0.06	-0.04
GALLBLADDER	3	0.93	3	0.90	0	0.00	1	2.27	0	0.00	2	2.40	0	0.00	-0.01	-0.01
PANCREAS	7	0.77	8	0.85	1	3.47	0	0.00	5	1.22	0	0.00	2	1.43	-0.06	-0.04
LUNG	54	0.94	69	1.17	15	7.94	6	0.76	23	0.88	16	1.09	9	1.06	-0.09	0.28
SKIN MELANOMA	6	0.86	8	1.11	2	9.67	0	0.00	4	1.28	2	1.09	0	0.00	-0.03	0.02
MESOTHELIOMA	6	3.12	6	3.03	0	0.00	1	3.99	2	2.33	3	5.95	0	0.00	0.12	0.11
KAPOSI SARCOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
SOFT TISSUE	5	3.36	5	3.25	0	0.00	0	0.00	3	4.45	1	2.59	1	4.42	0.10	0.10
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BREAST	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
PROSTATE	87	1.34	89	1.33	2	1.02	7	0.83	43	1.48	27	1.57	10	0.97	0.63	0.61
TESTIS	2	1.09	3	1.59	1	16.43	1	3.63	1	1.15	0	0.00	0	0.00	0.00	0.03
KIDNEY AND RENAL PELVIS	34	2.78	37	2.94	3	7.96	5	3.07	13	2.36	11	3.44	5	2.63	0.63	0.68
BLADDER AND URINARY TRACT	40	1.09	40	1.05	0	0.00	5	0.99	19	1.14	11	1.16	5	0.90	0.09	0.06
URINARY BLADDER	39	1.10	39	1.07	0	0.00	5	1.03	19	1.19	10	1.09	5	0.94	0.11	0.07
URINARY TRACT	1	0.70	1	0.68	0	0.00	0	0.00	0	0.00	1	2.68	0	0.00	-0.01	-0.01
BRAIN AND CENTRAL NERVOUS SYSTEM	11	2.19	11	2.12	0	0.00	0	0.00	7	3.06	3	2.32	1	1.34	0.17	0.16
THYROID	1	0.33	7	2.27	6	65.48	1	2.44	0	0.00	0	0.00	0	0.00	-0.06	0.11
HODGKIN LYMPHOMA	2	1.46	2	1.41	0	0.00	1	4.92	0	0.00	1	2.90	0	0.00	0.02	0.02
NON-HODGKIN LYMPHOMA	15	1.33	17	1.46	2	5.63	1	0.65	8	1.57	3	1.02	3	1.74	0.11	0.15
MYELOMA	6	1.39	7	1.58	1	7.17	1	1.71	2	1.03	2	1.78	1	1.53	0.05	0.07
LEUKAEMIAS	12	1.56	12	1.51	0	0.00	2	1.86	4	1.14	4	2.02	2	1.77	0.12	0.11
LYMPHOID LEUKAEMIAS	5	1.34	5	1.30	0	0.00	1	1.91	1	0.59	2	2.10	1	1.83	0.04	0.03
MYELOID LEUKAEMIAS	7	1.99	7	1.92	0	0.00	1	2.06	3	1.88	2	2.18	1	1.90	0.10	0.09
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
OTHER AND ILL DEFINED SITES	21	1.25	24	1.39	3	5.47	3	1.30	5	0.66	9	2.07	4	1.58	0.12	0.19

■ Decrease/Difetto ○ Observed cases ■ SIR Standardized Incidence Ratio ■ EAR Excess Absolute Risk
■ Increase/Eccesso ○ Casi osservati ■ Rapporto standardizzato di incidenza ■ Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE
THYROIDTHYROID
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

TIROIDE
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	21992		22925		22925		21992		19139		10109		4094		21992	22925
Person-years ▶	125847		129587		3741		17113		56997		33645		18092		125847	129587
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND THYROID	980	1.22	1033	1.25	53	2.52	129	1.36	379	1.12	273	1.20	199	1.39	1.40	1.61
HEAD AND NECK	8	0.71	10	0.86	2	6.81	2	1.50	4	0.84	1	0.31	1	0.49	-0.03	-0.01
ORAL CAVITY	3	0.53	3	0.52	0	0.00	2	3.06	0	0.00	0	0.00	1	0.96	-0.02	-0.02
PHARYNX	0	0.00	2	0.65	2	25.50	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.01
LARYNX	5	1.84	5	1.80	0	0.00	0	0.00	4	3.50	1	1.31	0	0.00	0.02	0.02
OESOPHAGUS	5	1.62	8	2.52	3	37.83	2	5.75	0	0.00	2	2.25	1	1.68	0.02	0.04
STOMACH	42	1.28	44	1.31	2	2.23	2	0.52	20	1.48	13	1.38	7	1.16	0.07	0.08
COLON RECTUM	122	1.15	125	1.15	3	1.10	13	1.08	60	1.37	31	1.01	18	0.90	0.13	0.12
COLON	91	1.21	93	1.21	2	1.05	9	1.06	42	1.37	26	1.20	14	0.98	0.13	0.12
RECTUM	31	0.99	32	1.00	1	1.23	4	1.10	18	1.39	5	0.56	4	0.70	0.00	0.00
LIVER	10	0.62	10	0.60	0	0.00	2	1.08	1	0.15	4	0.86	3	0.98	-0.05	-0.05
GALLBLADDER	9	0.73	10	0.79	1	3.00	1	0.69	4	0.79	0	0.00	4	1.74	-0.03	-0.02
PANCREAS	36	1.47	36	1.44	0	0.00	7	2.62	11	1.12	11	1.54	7	1.45	0.09	0.08
LUNG	68	1.43	88	1.81	20	17.09	12	2.27	21	1.08	17	1.24	18	1.99	0.16	0.30
SKIN MELANOMA	18	0.82	19	0.84	1	1.72	6	2.24	4	0.42	4	0.65	4	1.10	-0.03	-0.03
MESOTHELIOMA	2	0.95	3	1.39	1	19.43	1	4.28	1	1.17	0	0.00	0	0.00	0.00	0.01
KAPOSI SARCOMA	1	1.21	1	1.18	0	0.00	0	0.00	0	0.00	1	4.25	0	0.00	0.00	0.00
SOFT TISSUE	4	1.05	4	1.02	0	0.00	0	0.00	2	1.22	1	0.94	1	1.54	0.00	0.00
BONE	3	2.78	3	2.70	0	0.00	0	0.00	2	4.21	0	0.00	1	5.97	0.02	0.01
BREAST	327	1.22	333	1.21	6	0.85	36	1.12	143	1.25	88	1.18	60	1.31	0.47	0.45
CERVIX UTERI	9	0.59	10	0.64	1	2.26	1	0.50	4	0.59	1	0.24	3	1.32	-0.05	-0.04
CORPUS UTERI	58	1.33	59	1.31	1	0.87	7	1.33	19	1.02	22	1.79	10	1.31	0.11	0.11
OVARY	48	1.67	49	1.66	1	1.29	6	1.71	15	1.22	17	2.12	10	2.05	0.15	0.15
KIDNEY AND RENAL PELVIS	32	1.70	33	1.71	1	2.12	9	4.21	7	0.90	6	1.11	10	2.87	0.11	0.11
BLADDER AND URINARY TRACT	33	1.32	33	1.28	0	0.00	1	0.35	11	1.07	12	1.66	9	1.89	0.06	0.06
URINARY BLADDER	31	1.32	31	1.28	0	0.00	1	0.38	11	1.14	10	1.47	9	2.02	0.06	0.05
URINARY TRACT	2	1.29	2	1.26	0	0.00	0	0.00	0	0.00	2	4.40	0	0.00	0.00	0.00
BRAIN AND CENTRAL NERVOUS SYSTEM	11	0.88	11	0.86	0	0.00	1	0.66	2	0.38	5	1.44	3	1.40	-0.01	-0.01
THYROID	0	0.00	14	0.44	14	16.25	0	0.00	0	0.00	0	0.00	0	0.00	-0.25	-0.14
HODGKIN LYMPHOMA	6	1.70	6	1.65	0	0.00	1	1.97	4	2.43	1	1.09	0	0.00	0.02	0.02
NON-HODGKIN LYMPHOMA	37	1.22	38	1.22	1	1.27	5	1.41	14	1.10	11	1.28	7	1.29	0.05	0.05
MYELOMA	20	1.69	21	1.73	1	3.28	3	2.22	8	1.64	6	1.76	3	1.36	0.06	0.07
LEUKAEMIAS	24	1.42	25	1.44	1	2.19	3	1.49	9	1.27	10	2.08	2	0.67	0.06	0.06
LYMPHOID LEUKAEMIAS	5	0.71	5	0.69	0	0.00	2	2.36	1	0.34	2	1.00	0	0.00	-0.02	-0.02
MYELOID LEUKAEMIAS	18	2.07	19	2.13	1	4.33	1	0.97	7	1.92	8	3.24	2	1.29	0.07	0.08
OTHER LEUKAEMIAS	1	0.87	1	0.85	0	0.00	0	0.00	1	2.10	0	0.00	0	0.00	0.00	0.00
OTHER AND ILL DEFINED SITES	47	0.99	54	1.12	7	5.72	8	1.31	13	0.68	9	0.68	17	1.96	0.00	0.04

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio